NDLI: Targeting MYC dependence in cancer by inhibiting BET bromodomains

Content Provider	PubMed Central
Author	Mertz, Jennifer A. Conery, Andrew R. Bryant, Barbara M. Sandy, Peter Balasubramanian, Srividya Mele, Deanna A. Bergeron, Louise Sims, Robert J.
Abstract	The MYC transcription factor is a master regulator of diverse cellular functions and has been long considered a compelling therapeutic target because of its role in a range of human malignancies. However, pharmacologic inhibition of MYC function has proven challenging because of both the diverse mechanisms driving its aberrant expression and the challenge of disrupting protein–DNA interactions. Here, we demonstrate the rapid and potent abrogation of MYC gene transcription by representative small molecule inhibitors of the BET family of chromatin adaptors. MYC transcriptional suppression was observed in the context of the natural, chromosomally translocated, and amplified gene locus. Inhibition of BET bromodomain–promoter interactions and subsequent reduction of MYC transcript and protein levels resulted in G1 arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines. Exogenous expression of MYC from an artificial promoter that is resistant to BET regulation significantly protected cells from cell cycle arrest and growth suppression by BET inhibitors. MYC suppression was accompanied by deregulation of the MYC transcriptome, including potent reactivation of the p21 tumor suppressor. Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia. These findings demonstrate that pharmacologic inhibition of MYC is achievable through targeting BET bromodomains. Such inhibitors may have clinical utility given the widespread pathogenetic role of MYC in cancer.
Related Links	http://dx.doi.org/10.1073/pnas.1108190108
Ending Page	16674
Page Count	6
Starting Page	16669
File Format	PDF
ISSN	00278424
e-ISSN	10916490
Journal	Proceedings of the National Academy of Sciences of the United States of America
Issue Number	40
Volume Number	108
Language	English
Publisher	National Academy of Sciences
Publisher Date	2011-10-04
Access Restriction	Open
Rights Holder	National Academy of Sciences
Subject Keyword	General Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Multidisciplinary

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains

Selective inhibition of BET bromodomains

PFI-1 – A highly Selective Protein Interaction Inhibitor Targeting BET Bromodomains

Inhibition of Lapatinib-induced Kinome Reprogramming in ERBB2-positive Breast Cancer by Targeting BET Family Bromodomains

Targeting MYC dependence in cancer by inhibiting BET bromodomains.

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer

PVT1 dependence in cancer with MYC copy-number increase

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors

Targeting MYC dependence in cancer by inhibiting BET bromodomains

Similar Documents

Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains

Selective inhibition of BET bromodomains

PFI-1 – A highly Selective Protein Interaction Inhibitor Targeting BET Bromodomains

Inhibition of Lapatinib-induced Kinome Reprogramming in ERBB2-positive Breast Cancer by Targeting BET Family Bromodomains

Targeting MYC dependence in cancer by inhibiting BET bromodomains.

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer

PVT1 dependence in cancer with MYC copy-number increase

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors

Targeting MYC dependence in cancer by inhibiting BET bromodomains